$RPRX 90 DAYS STOCK PRICE FORECAST

Stock Price

About the Company

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma's current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates.

Exchange

NASDAQ

Website

www.royaltypharma.com

$2B

Total Revenue

51

Employees

$19B

Market Capitalization

15.20

Price/Earning ratio

Similar Companies

Name Ticker Market Capitalization (USD M) Revenue (USD M) Price/Book Price/Earning Net Margin (%)
Conversion Labs Inc CVLB 108548 35213 3.74 42.66 7.33
Royalty Pharma plc RPRX 18925 2239 2.81 15.20 43.40
Organon & Co. OGN 8844 7891 -4.56 5.07 22.06
Arvinas Inc ARVN 3725 21 7.48 -22.56 -782.93
Tilray Inc TLRY 3241 564 1.08 -8.14 -66.49
ATAI Life Sciences N.V. ATAI 2272 20 4.78 -10.40 -932.88
Cronos Group Inc CRON 2097 57 1.32 -14.52 -258.59
Usana Health Sciences Inc USNA 2079 1254 4.73 14.98 11.09
NRX Pharmaceuticals Inc NRXP 1170 2321 0.45 5.05 9.91
Phathom Pharmaceuticals Inc PHAT 1033 7.01 -6.45 None
Intersect ENT Inc XENT 893 103 21.65 -13.01 -66.55
Phibro Animal Health Corp. PAHC 893 833 3.70 16.25 6.53
Edgewise Therapeutics Inc EWTX 796 2.70 -29.55 None
Fulcrum Therapeutics Inc FULC 711 15 8.62 -9.63 -481.07
Pliant Therapeutics Inc PLRX 614 13 2.51 -7.16 -613.56
Cyteir Therapeutics Inc CYT 596 3.20 -20.62 None
Urovant Sciences Ltd UROV 503 -3.65 -3.08 None
Ikena Oncology Inc IKNA 404 10 2.18 -7.38 -551.28
Chromadex Corp CDXC 394 62 9.92 -16.62 -37.51
Provention Bio Inc PRVB 377 2.53 -2.94 None
Rain Therapeutics Inc RAIN 355 413 2.19 -11.66 123.20
Verrica Pharmaceuticals Inc VRCA 325 12 6.57 -8.92 -301.45
Evolus Inc EOLS 310 77 4.10 -2.08 -171.53
Adicet Bio Inc ACET 280 9 1.22 -4.97 -603.06
Terns Pharmaceuticals Inc TERN 252 1.40 -7.30 None
Milestone Pharmaceuticals Inc MIST 219 15 1.23 -7.37 -215.93
Kaleido Biosciences Inc KLDO 184 1 4.11 -2.07 None
Citius Pharmaceuticals Inc CTXR 179 2.24 -7.81 None
scPharmaceuticals Inc SCPH 167 119 2.45 -5.52 -27.05
Eyenovia Inc EYEN 143 6 16.29 -7.31 -324.94
Aquestive Therapeutics Inc AQST 142 42 -2.95 -2.21 -152.73
LifeMD Inc LFMD 139 64 -22.39 -1.00 -133.55
Eton Pharmaceuticals Inc ETON 124 15 6.13 -10.10 -74.52
Osmotica Pharmaceuticals Plc OSMT 122 190 2.37 -1.31 -47.85
Kala Pharmaceuticals Inc KALA 119 11 1.53 -0.94 None
Xeris Biopharma Holdings Inc XERS 111 34 12.19 -1.44 -248.46
Odonate Therapeutics Inc ODT 110 1.39 -0.94 None
Anebulo Pharmaceuticals Inc ANEB 102 7.93 -2.58 None
Opiant Pharmaceuticals Inc OPNT 100 37 3.03 -96.15 -3.06
Aerpio Pharmaceuticals Inc ARPO 99 15 2.98 -5.24 -28.77
Mannatech Inc MTEX 82 158 3.27 12.89 4.22
Natural Alternatives Internati NAII 80 179 1.07 7.90 6.03
India Globalization Capital In IGC 67 0 2.45 -7.60 -981.18
VYNE Therapeutics Inc VYNE 51 16 0.77 2.31 -554.66
Shineco Inc TYHT 44 3 2.17 -1.55 -159.60
Assertio Holdings Inc ASRT 36 117 0.49 -0.63 -38.05
Dermata Therapeutics Inc DRMA 36 -75.67 -7.32 None
Acasti Pharma Inc ACST 33 0 1.43 -1.66 -611.47
Nabriva Therapeutics Plc NBRV 29 12 0.88 -0.49 -452.55
Lexaria Bioscience Corp LEXX 27 1 3.76 -6.95 -445.15
Bio-Path Holdings Inc BPTH 26 0 1.19 -2.49 18.96
Reviva Pharmaceuticals Holding RVPH 25 1.41 -4.08 None
Baudax Bio Inc BXRX 25 1 -10.80 0.76 9.10
Trevi Therapeutics Inc TRVI 23 1.64 -0.66 None
Timber Pharmaceuticals Inc TMBR 20 0 8.75 0.67 -527.55
Hoth Therapeutics Inc HOTH 19 1.64 -2.02 None
Cyanotech Corp. CYAN 17 34 0.99 13.57 3.83
Sonoma Pharmaceuticals Inc. SNOA 11 17 3.32 -2.16 -31.96

First Week of December 17th Options Trading For Royalty Pharma (RPRX)

1d ago, source: Nasdaq

I nvestors in Royalty Pharma plc (Symbol: RPRX) saw new options begin trading this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

Royalty Pharma Declares Fourth-Quarter 2021 Dividend

4d ago, source: Associated Press

The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2021 of $0.17 per Class A ordinary share. The dividend will be paid on ...

Royalty Pharma Plc (RPRX)

4d ago, source: Investing.com

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and ...

RPRX December 2022 Options Begin Trading

8d ago, source: Nasdaq

Investors in Royalty Pharma plc (Symbol: RPRX) saw new options begin trading today, for the December 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to ...

Top 3 undervalued US biotech stocks to buy

7d ago, source: Invezz

The US biotech stock Sage Therapeutics seems to be bouncing back while Regeneron and Royalty Pharma stocks extend losses.

Fusion Antibodies fired up by R&D deal with US biotech business

13d ago, source: Proactive Investors

Fusion Antibodies PLC is in demand after it signed a collaborative R&D agreement with a US biotechnology start-up. The company, a spin out from Queen's University Belfast which helps develop ...

Oxford Biomedica Announces that Boehringer Ingelheim has Exercised Option Relating to a Novel Gene Therapy Treatment for Cystic Fibrosis

23h ago, source: YAHOO!Finance

Oxford Biomedica Announces that Boehringer Ingelheim has Exercised Option Relating to a Novel Gene Therapy Treatment for ...

Boehringer Ingelheim Exercises Option

1d ago, source: sharesmagazine

Oxford Biomedica Announces that Boehringer Ingelheim has Exercised Option Relating to a Novel Gene Therapy Treatment for Cystic Fibrosis. Oxford, UK - 19 October 2021: Oxford Biom ...

TRADING UPDATES: Victoria and Brickability report revenue progress

6d ago, source: London South East

Trident Royalties PLC - London-based mining royalty and streaming company - Following ... in USD143 million series B funding round in CinCor Pharma. "The proceeds from the Series B financing ...

Royalty Pharma Declares Fourth-Quarter 2021 Dividend

4d ago, source: Middle East North Africa Financial Network

(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, Oct. 15, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth ...

Royalty Pharma PLC Class A RPRX

5d ago, source: Morningstar%2c Inc.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Your Portfolio